Scientific Program , Eilat, Israel The 20th Annual Meeting of the Israeli Society of Clinical Oncology and Radiotherapy

תמליל

1 Scientific Program , Eilat, Israel The 20th Annual Meeting of the Israeli Society of Clinical Oncology and Radiotherapy

2 ISCORT wishes to express its gratitude to the following companies for their support of the 20 th ISCORT Annual Meeting: Platinum Sponsor Roche Gold Sponsor AstraZeneca MSD Novartis Pfizer Silver Sponsor Assuta Astellas BMS Eli Lilly Medison Oncotest Rhenium Rafa Sanofi Teva VaRay Bronze Sponsor AAA Ami Technologies Bayer Boehringer Ingelheim Desit Dexcel Pharma ISI Janssen Merck Nanostring Neopharm Perrigo Takeda Organizing Committee ISCORT 20 President: Baruch Brenner, MD Secretary, Medical Oncology: Noam Asna, MD Secretary, Radiation Oncology: Svetlana Zalmanova, MD Scientific Committee ISCORT 20 Chairman: Aaron Sulkes, MD Deputy Chairman: Gal Markel, MD, PhD Secretary: Assaf Moore, MD Jair Bar, MD, PhD Gil Bar-Sela, MD Alberto Gabizon, MD, PhD Ido Wolf, MD Marc Wygoda, MD Amir Sonnenblick, MD Jamal Zidan, MD Alona Zer, MD Rinat Yerushalmi, MD Dror Limon, MD Mor Moskovitz, MD Salem Billan, MD Tali Siegal, MD Tamar Safra, MD Beatrice Uziely, MD Aron Popovtzer, MD Raphael Catane, MD Daniel Keizman, MD Eli Rosenbaum, MD Ora Rosengarten, MD Katerina Shulman, MD Einat Shacham-Shmueli, MD הוועדה המארגנת נשיא הכנס: פרופ ברוך ברנר מזכיר האונקולוגיה הרפואית: ד ר נעם אסנה מזכירת הרדיותרפיה: ד ר סבטלנה זלמנובה הוועדה המדעית יו ר: פרופ אהרון סולקס סגן יו ר: פרופ גל מרקל מזכיר: ד ר אסף מור ד ר יאיר בר פרופ גיל בר-סלע פרופ אלברטו גביזון פרופ עידו וולף ד ר מרק ויגודה ד ר אמיר זוננבליק פרופ ג אמל זידאן ד ר אלונה זר פרופ רינת ירושלמי ד ר דרור לימון ד ר מור מושקוביץ ד ר סאלם בלאן פרופ טלי סיגל פרופ תמר ספרא פרופ ביאטריס עוזיאלי פרופ אהרון פופובצר פרופ רפאל קטן ד ר דניאל קייזמן ד ר אלי רוזנבאום ד ר אורה רוזנגרטן ד ר קטרינה שולמן ד ר עינת שחם-שמואלי Organizing Company החברה המארגנת I.M. Knasim Ltd. א.מ. כנסים בע"מ

3 Dear friends and colleagues, We are honored to cordially invite you to participate in the 20th Annual Meeting of the Israel Society of Clinical Oncology and Radiotherapy (ISCORT), which will be held in Eilat between January 7-11, The meeting s central theme will be which was selected as a result of the meeting s, Colleagues Colleagues Update unique nature, which does not focus on a single issue nor is it devoted mainly to learn from international opinion leaders. ISCORT is, in its essence, a meeting of Israeli colleagues in which oncologists specializing in one field update their colleagues on the latest developments in their area of interest. The choice to emphasize this nature of ISCORT Meeting derived not only from a wish but rather from the ability; we have witnessed substantial progress in the Oncology specialty in Israel in recent years, with the formation of a cadre of many specialists in the forefront of professional activity, who are also very capable of sharing their knowledge and expertise with their colleagues. ISCORT serves therefore, as an optimal platform for information exchange between Israeli colleagues. With this spirit, the Meeting will be conducted in Hebrew, except for sessions with a non- Israeli speaker. In parallel with enriching the knowledge in main oncology fields, particularly those in which substantial progress has taken place over the past year since the last ISCORT meeting, we have chosen this year to update several cross cutting topics which intrigue and concern most oncologists both in Israel and worldwide. Among these, we have included sessions about the potential costs of cancer screening, cancer biology and immunology and oligometastatic disease. Like prior organizing committees, we have also invested a major effort in creating an interesting and varied program. The meeting includes lectures, reviews of leading publications, multidisciplinary case presentations and discussions on controversial issues. In addition, outstanding works will be presented by oncologists from various Israeli institutions on clinical, translational and basic science topics. Notwithstanding the emphasis on the input of Israeli oncologists, we will also be honored to welcome guests from abroad who will undoubtedly enrich our understanding of specific topics in Oncology. We would like to express our special thanks to the Scientific Committee lead by Prof. Aaron Sulkes (chairman), Prof. Gal Markel (vice-chairman) and Dr. Assaf Moore (secretary) for their thorough work and commitment in selecting the best abstracts to be presented at the meeting. We look forward to meeting you in Eilat and wish you a pleasant and fruitful meeting. Sincerely, Prof. Baruch Brenner President Dr. Noam Asna Secretary (Medical Oncology) Dr. Svetlana Zalmanova Secretary (Radiotherapy) Oncology) חברים נכבדים, אנו מתכבדים להזמינכם להשתתף בכינוס של האיגוד הישראלי לאונקולוגיה קלינית ורדיותרפיה,,ISCORT 20 אשר יתקיים באילת בין 7-11 לינואר הנושא המרכזי בכינוס הוא עמיתים מעדכנים עמיתים, שנבחר לאור ייחודו של כנס ISCORT מכנסים אחרים; אין זה כנס המתמקד בתחום אחד באונקולוגיה ואין זה כנס בו מאזינים מקומיים רבים מתקבצים כדי לשמוע מוביל דעה עולמי. כנס ISCORT במהותו הוא מפגש נעים ומפרה של עמיתים ישראליים, בו אונקולוגים מתחום אחד מתעדכנים מעמיתיהם על ההתקדמויות האחרונות בתחום בו הם מתמקצעים. הבחירה להבליט אופיו זה של כנס ISCORT נבעה לא רק מהרצון, אלא גם מהיכולת; בשנים האחרונות התפתח מאד מקצוע האונקולוגיה בארץ, תוך התהוות שכבה של אנשי מקצוע רבים הניצבים בחזית העשייה בתחום או תת-תחום בו הם עוסקים, ואשר בורכו ביכולת להעביר את הידע והניסיון הרב שצברו לעמיתיהם. במצב זה, רק מתבקש שכנס ISCORT יהווה את הבמה המיטבית לחילופי מידע בין עמיתים ישראליים. ברוח זו, שפת הכנס תהיה ככלל בעברית, להוציא ישיבות בהן יהיה מרצה אורח. לצד העשרת הידע בתחומים המרכזיים באונקולוגיה, ובייחוד באלה בהם חלה התקדמות משמעותית בשנה שחלפה מכנס ISCORT הקודם, נבחרו השנה גם מספר נושאים חוצי-תחומים עדכניים, המסקרנים ומטרידים בו זמנית את מרבית האונקולוגים בארץ ובעולם. בין אלה נכללו המחירים האפשריים של בדיקות סקר, הביולוגיה והאימונולוגיה של מחלת הסרטן, והמחלה האוליגו-גרורתית. בדומה לוועדות מארגנות קודמות, גם אנו השקענו מאמץ רב כדי לבנות תכנית מדעית מעניינת ומגוונת. הכינוס מורכב מהרצאות, סקירות של פרסומים מובילים, דיוני מקרים רב-תחומיים, ודיונים בנושאים הנתונים במחלוקת. כמו כן, יוצגו עבודות מצטיינות ממרכזים שונים בארץ, מתחומי מחקר קליני, תרגומי ובסיסי. למרות הדגש על מרצים ישראליים, עדיין יכבדו אותנו בהשתתפותם גם אורחים מחו ל, אשר ללא ספק יעשירו את הבנתנו בנושאים מסוימים באונקולוגיה. בהזדמנות זו נרצה להודות באופן מיוחד לוועדה המדעית בראשותם של פרופ אהרון סולקס )יו ר הועדה(, פרופ גל מרקל )סגן יו ר( וד ר אסף מור )מזכיר(, על עבודה יסודית ביותר בבחירת התקצירים אשר יוצגו בכינוס. מצפים לכם באילת ומאחלים לכולם עניין והנאה כאחד. בברכה, פרופ ברוך ברנר נשיא הכינוס ד ר נעם אסנה מזכיר האונקולוגיה ד ר סבטלנה זלמנובה מזכירת הרדיותרפיה

4 Tuesday, January 7, Opening Session Moderator: Noam Asna, MD Barzilai Medical Center, Ashkelon, Israel Welcome Baruch Brenner, MD Wilmosh Mermershtain, MD Chairman, ISCORT Resident Recognition Award Avraham Kuten, MD Chair, Israel Cancer Association, Givatayim, Israel Best ISCORT Abstracts and Publications Awards Moderator: Aaron Sulkes, MD Radiation Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer Merav A. Ben David, MD Assuta Medical Center, Tel-Aviv, Israel Adaptation of Colon Cancer Cells to the Brain Microenvironment: The Role of IRS2 Ido Wolf, MD Incidence and Risk Factors of Arterial Thromboembolism (ATE) and Venous Thromboembolism (VTE) in Non-Small Cell Lung Cancer (NSCLC) Alona Zer, MD Best Publications 2019 Keynote Lecture Moderator: Miri Ziv Vice Chairman, Israel Cancer Association, Givatayim, Israel Cancer Screening: Benefits only? Otis Webb Brawley, MD Johns Hopkins University, Baltimore, USA Dinner

5 Wednesday, January 8, Meet the Professor - SBRT Tarshish A Hall Raphael Pfeffer, MD Assuta Medical Center, Tel-Aviv, Israel Supported by Assuta Medical Centers Gastro-Intestinal Malignancies - Part I Moderators: Ofer Purim, MD Assuta Medical Center, Ashdod, Israel Yaacov Lawrence, MD Current Treatment of Advanced Pancreatic Cancer Talia Golan, MD Supported by AstraZeneca and MSD Radiotherapy in Colorectal Cancer Ross Abrams, MD Current Treatment of Metastatic Esophago- Gastric Cancers Ayala Hubert, MD Supported by MSD Pro & Con: Is There a Role for Radiotherapy in Pancreatic Cancer? Moderator: Katerina Shulman, MD Hillel Yaffe Medical Center, Hadera, Israel Pro: Raphael Pfeffer, MD Assuta Medical Center, Tel-Aviv, Israel Con: Einat Shacham-Shmueli, MD Supported by Assuta Medical Centers Tumor Board - Esophageal Cancer Moderator: Sharon Pelles, MD Panel: Alon Ben-Nun, MD, PhD Marc Wygoda, MD Nirit Yarom, MD Shamir (Asaf Harofe) Medical Center, Tzrifin, Israel Coffee Break Gastro-Intestinal Malignancies - Part II Moderators: Sofia Man, MD Soroka Medical Center, Beer Sheva, Israel Eyal Fenig, MD Current Treatment of Advanced HCC Ravit Geva, MD Supported by Roche Best of GI 2019 Valeria Seministy, MD

6 Original Abstracts Part I: A Critique of the Fragility Index in Oncological Trials Tomer Meirson, MD, PhD student Bar-Ilan University, Faculty of Medicine in the Galilee A Phase II Randomized, Double-Blind, Placebo-controlled Trial of Namodenoson as 2nd-line Therapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis Solomon M Stemmer, MD Pharmacokinetics of Mitomycin-c Lipidic Prodrug Entrapped in Liposomes (Promitil) and Clinical Correlations in Metastatic Colorectal Cancer Patients Alberto Gabizon, MD, PhD Shaare Zedek Medical Center, Jerusalem, Israel When Do Colorectal Tumors Die Following Therapy? Albert Grinshpun, MD Next Generation Sequencing in Salivary Gland Carcinoma - Do Targetable Alterations Lead to a Therapeutic Advantage? A Multicenter Experience Assaf Moore, MD Keynote Lecture Moderator: Jacob Schachter, MD Cancer Immunology Antoni Ribas, MD, PhD University of California Los Angeles, Los Angeles, USA Supported by MSD Lunch Keynote Lecture Moderator: Jacob Schachter, MD Resistance to Immunotherapy Antoni Ribas, MD, PhD University of California Los Angeles, Los Angeles, USA Supported by MSD Genito-Urinary Malignancies - Part I Moderators: Daniel Goldstein, MD Eliahu Gez, MD Ziv Medical Center, Safed, Israel Systemic Therapy in High Risk Prostate Cancer Eli Rosenbaum, MD Supported by Teva Radiotherapy in High Risk Prostate Cancer Tomer Charas, MD Supported by Electa Upfront Management of Metastatic RCC: IO- VEGFi or IO-IO Victoria Neiman, MD Supported by BMS and MSD

7 Pro & Con: Organ Preservation in Bladder Cancer Moderator: David Sarid, MD Pro: Mark Wygoda, MD Con: Ofer Yosepovich, MD Metastatic Bladder Cancer Avivit Peer, MD Supported by MSD Coffee Break Genito-Urinary Malignancies - Part II Moderators: Wilmosh Mermershtain, MD Chairman, ISCORT Zvi Symon, MD Tumor Board- Prostate Cancer Moderator: Raanan Berger, MD, PhD Panel: Tomer Charas, MD Daniel Keizman, MD Avivit Peer, MD Eli Rosenbaum, MD Supported by Jansen Best of GU 2019 Keren Rouvinov, MD Soroka Medical Center, Beer Sheva, Israel Supported by Astellas Original Abstracts Part II: The Role of Myc in Interferon-γ Signaling Inhibition and Immunotherapy Resistance in Advanced Melanoma Patients Ettai Markovits, MD Sheba Medical Center, Ramat Gan, Israel Real-World Analysis of Cabozantinib for Metastatic Renal Cell Carcinoma (mrcc) Patients in Israel: Outcomes and Associated Factors Keren Rouvinov, MD Soroka Medical Center, Beer Sheva, Israel The Association between Allopurinol Use and Urologic Malignancies: A Nested Case-Control Study Daniel Keizman, MD Radiosurgery Compared To External Beam Radiotherapy for Localized Spine Metastasis: Phase III Results of NRG Oncology/RTOG 0631 Aaron Allen, MD A Phase 2 Single Arm Study of Nivolumab and Ipilimumab (Nivo/Ipi) in Previously Treated Classical Kaposi Sarcoma (CKS) Alona Zer, MD

8 Thursday, January 9, ISCORT Discussion: Residency Moderator: Wilmosh Mermershtain, MD Chairman, ISCORT Meet the Professor - Melanoma Tarshish A Hall Peter Mohr, MD Elbe Kliniken, Stade, Germany Supported by Novartis Lung Cancer - Part I Moderators: Abed Agbarya, MD Bnai Zion Medical Center, Haifa, Israel Tatiana Rabin, MD Molecular-Based Treatment of NSCLC Mor Moskovitz, MD Supported by Roche Non-Surgical Treatment in Stage III NSCLC Michael Brada, FRCP, FRCR, DSc Radiation Oncology, University of Liverpool, GB Sequential Treatment Lines in NSCLC Nir Peled, MD, PhD Soroka Medical Center, Beer Sheva, Israel Pro & Con: Is Surgery Mandatory in Stage I Lung Cancer? Moderator: Maya Gottfried, MD Meir Medical Center, Kfar Saba, Israel Pro: Aaron Allen, MD Con: Alon Ben-Nun, MD, PhD Tumor Board - NSCLC Moderator: Jair Bar, MD, PhD Panel: Alon Ben-Nun, MD, PhD Michael Brada, FRCP, FRCR, DSc Radiation Oncology, University of Liverpool, GB Maya Gottfried, MD Meir Medical Center, Kfar Saba, Israel Dov Hershkovitz, MD Natasha B. Leighl, M.D Princess Margaret Hospital, Toronto, Canada Damian Urban, MD Supported by AstraZeneca and MSD Coffee Break Lung Cancer - Part II Moderators: Ofer Merimsky, MD Amichai Meirovich, MD Neuroendocrine Carcinomas and SCLC Alona Zer, MD Supported by Roche Immunotherapy in Lung Cancer: Future Perspectives Natalie Maimon-Rabinovich, MD Meir Medical Center, Kfar Saba, Israel Supported by MSD Best of Lung 2019 Sivan Shamay, MD Supported by AstraZeneca

9 Original Abstracts Part III: Venous Thromboembolism in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Check-Point Inhibitors A Retrospective Cohort Study Oded Icht, MD Comparative Effectiveness of Intensity Modulated Radiation Therapy to 3-Dimensional Conformal Radiation in Locally Advanced Lung Cancer: Pathological and Clinical Outcomes Sarit Appel, MD Sheba Medical Center, Ramat Gan, Israel The Impact of an Oncologist-Supervised Cancer Diagnostic Clinic on Time-to-Treatment (TTT) in Advanced Lung Cancer Opher Globus, MD Sheba Medical Center, Ramat Gan, Israel Efficacy of Immune Check-Point Inhibitors (ICPi) in Large Cell Neuroendocrine Tumors (LCNET) of Lung Shira Sherman, MD Davidoff Cancer Center, Rabin Medical Center, Israel Ablation of Cx3cr1-expressing Tumor-associated Macrophages Significantly Increases Radiation Sensitivity in a Murine Lung Cancer Model Uri Amit, MD, MPH, PhD Sheba Medical Center, Ramat Gan, Israel Lunch (Continue in Tarshish Hall) Keynote Lecture Moderator: Jamal Zidan, MD Ziv Medical Center, Safed, Israel Cancer Development Heinz-Josef Lenz, MD USC Norris Comprehensive Cancer Center, Los Angeles, USA Oligometastatic Disease Special Session Moderators: Neil Friedman, MD Laniado Hospital, Netanya, Israel Salem Billan, MD The Biology of Oligometastatic Disease Yuval Shaked, PhD Technion Faculty of Medicine, Haifa, Israel Radiotherapy for Oligometastatic Disease Benjamin Movsas, MD Radiation Oncology, Henry Ford Hospital, Detroit, USA Supported by VaRay Systemic Treatment of Oligometastatic Disease Ido Wolf, MD Miscellaneous Part I Moderators: Ronen Brenner, MD Wolfson Medical Center, Holon, Israel Hovav Nechushtan, MD Integrative Oncology Integrating Epigenetics, Tumor Microenvironment, and the Patient as a Whole Ofer Caspi, MD, PhD Molecular Profiling in 2020: Wishes and Facts Natasha B. Leighl, M.D Princess Margaret Hospital, Toronto, Canada Supported by Oncotest Rhenium

10 Coffee Break Miscellaneous Part II Moderators: Gil Bar-Sela, MD HaEmek Medical Center, Afula, Israel Dror Limon, MD Adjuvant Treatment of Melanoma Peter Mohr, MD Elbe Kliniken, Stade, Germany Supported by Novartis Treatment of Metastatic Melanoma Michal Lotem, MD Supported by BMS 16:20-16:40 Treatment of Advanced Non-Melanoma Skin Cancer Gil Tauber, MD Rabin Medical Center, Petach Supported by Sanofi 16:40-17:00 Metastatic H&N Cancer Aron Popovtzer, MD Supported by MSD 17:00-17:20 Advances in the Treatment of Ovarian Cancer Tamar Safra, MD Supported by AstraZeneca and MSD 17:20-17:40 Cannabis: Myth or Reality? Ora Rosengarten, MD Shaare Zedek Medical Center, Jerusalem, Israel Friday, January 10, Meet the Professor - Breast Cancer Tarshish A Hall Rinat Yerushalmi, MD Supported by Roche Breast Part I Moderators: Ella Evron, MD Kaplan Medical Center, Rehovot, Israel Eli Sapir, MD Assuta Medical Center, Ashdod, Israel Escalation & De-Escalation Strategies - The Challenging Journey Towards Precision Medicine in Early Breast Cancer Shani Paluch-Shimon, MD Shaare Zedek Medical Center, Jerusalem, Israel Supported by Roche Modern RT in Breast Cancer Yasmin Korzets, MD Targeted Therapies in Metastatic Breast Cancer Amir Sonnenblick, MD, PhD Supported by Novartis Pro & Con: Low Dose Tamoxifen for Every Woman with High Risk for Breast Cancer Moderator: Tamar Peretz, MD Pro: Rinat Yerushalmi, MD Con: Larissa Rivo, MD Assuta Medical Center, Ashdod, Israel

11 Tumor Board - Breast Cancer Moderator: Panel: Noa Efrat Ben-Baruch, MD Kaplan Medical Center, Rehovot, Israel Einav Gal Yam, MD, PhD Irina Jeveliuk, MD Assuta Medical Center, Tel-Aviv, Israel Bella Kaufman, MD Yasmin Korzets, MD Tanir M. Allweis, MD Kaplan Medical Center, Rehovot, Israel Shani Paluch-Shimon, MD Shaare Zedek Medical Center, Jerusalem, Israel Gilad W. Vainer MD, PhD Supported by Roche Coffee Break Breast Cancer Part II Moderators: Ayelet Shay, MD Galilee Medical Center, Nahariya, Israel Liana Abdach, MD Pro & Con: IORT in Early Breast Cancer Moderator: Merav Ben David, MD Assuta Medical Center, Tel-Aviv, Israel Pro: Yonina Tova, MD Assuta Medical Center, Tel-Aviv, Israel Con: Orit Kaidar-Person, MD Supported by Medison Best of Breast 2019 Nava Siegelmann-Danieli, MD Maccabi Health Services, Israel Supported by Lilly Original Abstracts Part IV: Evolution in the Risk of Adverse Events of Adjuvant Endocrine Therapy in Postmenopausal Women with Early-Stage Breast Cancer Daniel Reinhorn, MD Ethnicity, Recurrence Score (RS) Distribution, and Clinical Outcomes in ER+ HER2-Negative Breast Cancer (BC) Patients Tested Through Clalit Health Services (CHS) in Israel Gil Bar-Sela, MD HaEmek Medical Center, Afula, Israel De-Escalating Adjuvant Trastuzumab in HER2 Positive Early-Stage Breast Cancer: A Systemic Review and Meta-analysis Hadar Goldvaser, MD Deconstructing Klotho: From Experimental Model to Developing Novel Anti-Neoplastic Therapy Hagai Ligumsky, MD, PhD Sourasky Medical Center, Tel Aviv, Israel Prognostic & Predictive Implications of Absolute Lymphocytes Count 7 Days After Adoptive Cell Therapy with Tumor Infiltrating Lymphocytes Guy Ben-Betzalel, MD Sheba Medical Center, Ramat Gan, Israel

12 Grant Awards Moderator: Gal Markel, MD, PhD Sheba Medical Center, Ramat Gan, Israel 12:45 Closing Remarks 13:00 Lunch 13:30-15:00 ISCORT Forum Meeting

13 This program was printed with the support of Roche Pharmaceuticals (Israel) Ltd.